-
1.发明授权公开(公告)号：US06586194B1
公开(公告)日：2003-07-01
申请号：US09665063
申请日：2000-09-19
IPC分类号： G01N3300
CPC分类号： G01N33/573 , C12Q1/50 , Y10S435/81
摘要： A method for measuring the activity of creatine kinase MB (CK-MB) isozyme which is accurate, high in specificity, convenient, by inhibiting the activity of a mitochondria localized creatine kinase (mCK) isozyme to avoid the influence of mCK and a measurement reagent therefor.
摘要翻译： 通过抑制线粒体局部肌酸激酶（mCK）同功酶的活性来测定肌酸激酶MB（CK-MB）同功酶的活性，该方法准确，特异性高，方便，以避免mCK和测定试剂的影响 因此。
-
公开(公告)号：US07148063B2
公开(公告)日：2006-12-12
申请号：US10424740
申请日：2003-04-29
CPC分类号： C07K16/40 , Y10S435/975
摘要： The object of the present invention is to provide a method for more accurately assaying the enzyme activities of mCK isozymes and a method for separately assaying the enzyme activities of CK isozymes by separately assaying the enzyme activities of ubiquitous mCK (umCK) and sarcomeric mCK (smCK). The above object is attained by an assay using an antibody that specifically recognizes umCK protein. In addition, other anti-mCK antibodies (e.g., anti-smCK antibody) and/or anti-human CK-M-inhibiting antibody can also be used. The above antibody is a polyclonal antibody or a monoclonal antibody. As a result of these antibodies, a monoclonal antibody (U1-1881) that is capable of specifically recognizing human umCK and is produced by a hybridoma having a deposition number of FERM BP-8342 is provided.
-
3.发明授权Immunassay of non-A, non-B hepatitis virus-related antigens, monoclonal antibodies for use therein, and hybridomas producing the antibodies 失效非A型非乙型肝炎病毒相关抗原的免疫测定，用于其中的单克隆抗体和产生抗体的杂交瘤
公开(公告)号：US5871904A
公开(公告)日：1999-02-16
申请号：US501195
申请日：1995-07-11
申请人： Tomiko Kashiwakuma , Shintaro Yagi , Akira Hasegawa , Tadahiro Kajita , Yohsuke Ohta , Hiroyuki Mori
发明人： Tomiko Kashiwakuma , Shintaro Yagi , Akira Hasegawa , Tadahiro Kajita , Yohsuke Ohta , Hiroyuki Mori
IPC分类号： G01N33/53 , C07K14/18 , C07K16/10 , C12N5/10 , C12N5/20 , C12P21/08 , G01N33/576 , G01N33/577 , C12Q1/70 , C07K16/08 , C12N5/12
CPC分类号： C07K14/005 , C07K16/10 , C12N2770/24222
摘要： This invention concerns a monoclonal antibody having binding specificity for an antigenic determinant site on core structural protein from Non-A,Non-B hepatitis virus (NANBV); a hybridoma cell line capable of producing the monoclonal antibody; a process for the preparation of the monoclonal antibody; an immunoassay of NANBV-related antigens by use of the monoclonal antibody; and a test kit for use in the immunoassay. The preferred monoclonal antibody is 5E3, 5F11, 515S or 1080S. The monoclonal antibody can specifically recognize the NANBV core structural protein in sera from patients with Non-A,Non-B hepatitis thereby being served extensively as an antibody in various immunological reagents for definitive diagnosis of Non-A, Non-B hepatitis.
摘要翻译： 本发明涉及对来自非A非乙型肝炎病毒（NANBV）的核心结构蛋白上的抗原决定簇位点具有结合特异性的单克隆抗体; 能够产生单克隆抗体的杂交瘤细胞系; 一种制备单克隆抗体的方法; 通过使用单克隆抗体对NANBV相关抗原的免疫测定; 和用于免疫测定的测试试剂盒。 优选的单克隆抗体是5E3,5F11,515S或1080S。 单克隆抗体可以特异性识别来自非A型非乙型肝炎患者的血清中的NANBV核心结构蛋白，从而作为用于非A型非乙型肝炎确定诊断的各种免疫试剂中的抗体作为抗体。
-
公开(公告)号：US07871621B2
公开(公告)日：2011-01-18
申请号：US11435835
申请日：2006-05-18
申请人： Kazuhiko Takeda , Tadahiro Kajita , Ayumi Asaeda
发明人： Kazuhiko Takeda , Tadahiro Kajita , Ayumi Asaeda
CPC分类号： G01N33/576 , C07K16/082 , G01N2333/02
摘要： An anti-HBs monoclonal antibody is described herein. This antibody can bind to the following: (i) a wild type HBsAg; (ii) at least one mutant HBsAg selected from the group consisting of a first mutant HBsAg and a second mutant HBsAg; and (iii) at least one mutant HBsAg selected from the group consisting of a third mutant HBsAg and a fourth mutant HBsAg. The first mutant HBsAg has a mutation at position 120. The second mutant HBsAg has a mutation at position 141. The third mutant HBsAg has a substitution to a lysine at position 118. The fourth mutant HBsAg has only one mutation at position 144 and an amino acid at the position 144 is substituted by a glutamic acid.
摘要翻译： 本文描述了抗HBs单克隆抗体。 该抗体可以结合如下：（i）野生型HBsAg; （ii）至少一种选自第一突变体HBsAg和第二突变体HBsAg的突变体HBsAg; 和（iii）至少一种选自第三突变体HBsAg和第四突变体HBsAg的突变体HBsAg。 第一突变体HBsAg在位置120处具有突变。第二突变体HBsAg在141位具有突变。第三突变体HBsAg在位置118具有赖氨酸取代。第四突变体HBsAg在144位仅具有一个突变，氨基 位置144处的酸被谷氨酸取代。
-
公开(公告)号：US06830896B2
公开(公告)日：2004-12-14
申请号：US10294558
申请日：2002-11-15
申请人： Noboru Kaneko , Ryuko Matsuda , Tadahiro Kajita
发明人： Noboru Kaneko , Ryuko Matsuda , Tadahiro Kajita
IPC分类号： G01N33543
CPC分类号： G01N33/6893 , G01N2333/4718 , Y10S436/811
摘要： The present invention provides a process and regent for analyzing annexin-V, wherein the measurement of a concentration of annexin-V can be easily carried out without need for addition of chemicals for inhibiting the bonding of various proteins with calcium ion and for adjusting a specimen solution to the specimen at a measuring stage, and a process and medicine for diagnosing an internal organ disorder based on the analyzing process and regent. A urine is brought into contact with an anti-annexin-V monoclonal antibody to perform an antigen-antibody reaction of annexin-V in the urine with the anti-annexin-V monoclonal antibody, thereby forming an annexin-V antigen/anti-annexin-V monoclonal antibody complex, and the amount of the formed annexin-V antigen/anti-annexin-V monoclonal antibody complex is quantitatively measured. Thus, it is possible to carry out the measurement of the concentration of annexin-V in the urine, and it is possible to carry out the diagnosis of an internal organ disorder such as a disseminated intravascular coagulation syndrome, the diagnose of acute nephritis and the like by a analyzed value of concentration of annexin-V measured in the urine.
摘要翻译： 本发明提供了用于分析膜联蛋白-V的方法和试剂，其中可以容易地进行膜联蛋白-V浓度的测量，而不需要添加用于抑制各种蛋白质与钙离子结合的化学物质和用于调节样品 在测量阶段对标本的溶液，以及基于分析过程和摄取的诊断内脏器官障碍的过程和药物。 使尿液与抗膜联蛋白-V单克隆抗体接触，进行尿中与膜联蛋白-V单克隆抗体的膜联蛋白-V的抗原 - 抗体反应，从而形成膜联蛋白-V抗原/抗 - 膜联蛋白 -V单克隆抗体复合物，并定量测定形成的膜联蛋白-V抗原/抗 - 膜联蛋白-V单克隆抗体复合物的量。 因此，可以进行尿中膜联蛋白-V浓度的测定，可以进行内部器官功能障碍的诊断，例如弥漫性血管内凝血综合征，急性肾炎诊断和 如通过在尿液中测量的膜联蛋白-V浓度的分析值。
-
6.发明申请METHOD FOR MEASUREMENT OF SARS VIRUS NUCLEOCAPSID PROTEIN, REAGENT KIT FOR THE MEASUREMENT, TEST DEVICE, MONOCLONAL ANTIBODY DIRECTED AGAINST SARS VIRUS NUCLEOCAPSID PROTEIN, AND HYBRIDOMA CAPABLE OF PRODUCING THE MONOCLONAL ANTIBODY 审中-公开用于测量SARS病毒核蛋白质蛋白的方法，用于测量的试剂盒，测试装置，针对SARS病毒核蛋白质蛋白的单克隆抗体和产生单克隆抗体的混合物公开(公告)号：US20090280507A1
公开(公告)日：2009-11-12
申请号：US12090055
申请日：2006-10-11
IPC分类号： G01N33/573 , G01N33/536 , G01N33/543 , C07K16/08 , C12N5/16
CPC分类号： G01N33/56983 , C07K14/005 , C07K16/10 , C12N2770/20022
摘要： The present invention provides a method for measuring SARS virus nucleocapsid protein (SARS-NP) using first and second antibodies both binding specifically to SARS-NP, wherein the first or second antibody is an antibody recognizing an epitope located in a region (Region C) of amino acid 283 to 422 from the N-terminus of the amino acid sequence of SARS-NP.
摘要翻译： 本发明提供了使用特异性结合SARS-NP的第一和第二抗体测定SARS病毒核壳蛋白（SARS-NP）的方法，其中第一或第二抗体是识别位于区域（区域C）中的表位的抗体， 从SARS-NP的氨基酸序列的N末端的氨基酸283至422。
-
公开(公告)号：US20060264604A1
公开(公告)日：2006-11-23
申请号：US11435835
申请日：2006-05-18
申请人： Kazuhiko Takeda , Tadahiro Kajita , Ayumi Asaeda
发明人： Kazuhiko Takeda , Tadahiro Kajita , Ayumi Asaeda
IPC分类号： C07K14/00 , C07K16/00 , C07K1/00 , A61K38/00 , C07K17/00 , C07K2/00 , C07K4/00 , C07K5/00 , C07K7/00
CPC分类号： G01N33/576 , C07K16/082 , G01N2333/02
摘要： An anti-HBs monoclonal antibody is described herein. This antibody can bind to the following: (i) a wild type HBsAg; (ii) at least one mutant HBsAg selected from the group consisting of a first mutant HBsAg and a second mutant HBsAg; and (iii) at least one mutant HBsAg selected from the group consisting of a third mutant HBsAg and a fourth mutant HBsAg. The first mutant HBsAg has a mutation at position 120. The second mutant HBsAg has a mutation at position 141. The third mutant HBsAg has a substitution to a lysine at position 118. The fourth mutant HBsAg has only one mutation at position 144 and an amino acid at the position 144 is substituted by a glutamic acid.
摘要翻译： 本文描述了抗HBs单克隆抗体。 该抗体可以结合如下：（i）野生型HBsAg; （ii）至少一种选自第一突变体HBsAg和第二突变体HBsAg的突变体HBsAg; 和（iii）至少一种选自第三突变体HBsAg和第四突变体HBsAg的突变体HBsAg。 第一突变体HBsAg在位置120处具有突变。第二突变体HBsAg在141位具有突变。第三突变体HBsAg在位置118具有赖氨酸取代。第四突变体HBsAg在144位仅具有一个突变，氨基 位置144处的酸被谷氨酸取代。
-
8.发明授权
公开(公告)号：US5767247A
公开(公告)日：1998-06-16
申请号：US669509
申请日：1996-10-22
申请人： Noboru Kaneko , Ryuko Matsuda , Tadahiro Kajita , Yohsuke Ohta
发明人： Noboru Kaneko , Ryuko Matsuda , Tadahiro Kajita , Yohsuke Ohta
CPC分类号： C07K16/18 , G01N2333/4718
摘要： Using human annexin-V or human annexin-V plus dog annexin-V as antigen(s), hybridoma cell lines are prepared which are capable of producing anti-annexin-V monoclonal antibodies having a binding specificity to antigenic determinant site on annexin-V as antigenic protein and belonging to immunoglobulin G class. By the hybridoma cell lines are produced the anti-annexin-V monoclonal antibodies, with which a diagnostic agent is provided for diagnosis of myocardial infarction and angina pectoris. There is also provided diagnosis of myocardial infarction and angina pectoris using a first and a second monoclonal antibodies produced by the hybridoma cell lines to quantitate human annexin-V in a sample, in which an antigen-antibody reaction on annexin-V in the sample is caused with the first anti-annexin-V monoclonal antibody to form an annexin-V antigen/anti-annexin-V monoclonal antibody complex, the antigenic site of annexin-V of the formed annexin-V antigen/annexin-V monoclonal antibody complex is allowed to be bound with a labeled anti-annexin-V polyclonal or second monoclonal antibody so as to form a labeled form of said annexin-V antigen/anti-annexin-V monoclonal antibody complex bound with the polyclonal or the second monoclonal antibody, and the labeled form of the complex is quantitatively analyzed.
摘要翻译： PCT No.PCT / JP95 / 02305 Sec。 371日期1996年10月22日第 102（e）日期1996年10月22日PCT 1995年11月10日PCT PCT。 出版物WO96 / 15152 日期1996年5月23日使用人膜联蛋白-V或人膜联蛋白-V加狗膜联蛋白-V作为抗原，制备能够产生对抗原决定簇位点具有结合特异性的抗叶绿体-V单克隆抗体的杂交瘤细胞系 对膜联蛋白-V作为抗原蛋白，属于免疫球蛋白G类。 通过杂交瘤细胞系产生抗膜联蛋白-V单克隆抗体，通过该单克隆抗体提供用于诊断心肌梗塞和心绞痛的诊断剂。 还提供使用由杂交瘤细胞系产生的第一和第二单克隆抗体来定量样品中的人膜联蛋白-V的心肌梗塞和心绞痛的诊断，其中样品中对膜联蛋白-V的抗原 - 抗体反应是 由第一抗膜联蛋白-V单克隆抗体形成膜联蛋白-V抗原/抗 - 膜联蛋白-V单克隆抗体复合物，形成的膜联蛋白-V抗原/膜联蛋白-V单克隆抗体复合物的膜联蛋白-V的抗原位点是 允许与标记的抗 - 膜联蛋白-V多克隆或第二单克隆抗体结合，以形成与多克隆或第二单克隆抗体结合的所述膜联蛋白-V抗原/抗 - 膜联蛋白-V单克隆抗体复合物的标记形式，以及 定量分析复合物的标记形式。
-
-
-
-
-
-
-
搜索结果
8 条记录 (耗时 0.019 秒)
